Gene
CBL
CBL is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (2), Trial mentions (32), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CBL. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 6 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 6 of 8,875 | 0.07% | not measured | |
| 2024 | 3 of 8,597 | 0.03% | not measured | |
| 2023 | 5 of 8,275 | 0.06% | 14 of 11,460 | 0.12% |
| 2022 | 3 of 8,285 | 0.04% | 15 of 13,598 | 0.11% |
| 2021 | 4 of 8,692 | 0.05% | 16 of 15,045 | 0.11% |
| 2020 | 4 of 7,640 | 0.05% | 14 of 14,459 | 0.10% |
| 2019 | 1 of 7,300 | 0.01% | 14 of 12,159 | 0.12% |
| 2018 | 2 of 6,927 | 0.03% | 16 of 11,854 | 0.13% |
| 2017 | 0 of 6,558 | 0.00% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
Assay-provider ledger (2)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | February 20, 2015 |
| Illumina | Unclassified | No clinical or analytical validation recorded for this pair | 1 | February 20, 2015 |
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CBL (Y371H,C384R) | Dasatinib | response-associated | Myelodysplastic/Myeloproliferative Neoplasm | Cancer Genome Interpreter |
| CBL (Y371H,C384R) | Jak Inhibitors | response-associated | Myelodysplastic/Myeloproliferative Neoplasm | Cancer Genome Interpreter |
Trial mentions (32)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02823210 | Trial biospecimen (AACT) |
| NCT06284460 | Trial eligibility (AACT) |
| NCT06247787 | Trial eligibility (AACT) |
| NCT04409639 | Trial eligibility (AACT) |
| NCT07032727 | Trial eligibility (AACT) |
Showing 5 of 32 trial mentions.
Target-disease associations (590)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AKT2-related familial partial lipodystrophy | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Abnormality of the cardiovascular system | phenotype | Variant curation (ClinVar / EVA) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 590 associations.
Vendor sourcing (136)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Canonical splice site: predicted to alter splicing and result in a ... | View ClinVar record SCV002058377.2 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The CBL c.2606A>G; p.Tyr869Cys variant (rs758291160), to our knowledge, is not reported in the medical literature or gene specific databases. This variant is... | View ClinVar record SCV004563269.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Ability to comprehend the investigational nature of the study and provide informed consent (i.e., participant or legally authorized representative \[LAR... | View trial NCT06504459 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | CBL | View trial NCT06504459 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1210T>C (p.C404R) alteration is located in coding exon 8 of the CBL gene. This alteration results from a T to C substitution at nucleotide position 121... | View ClinVar record SCV001444949.3 |
Showing 5 of 136 sourcing records.
Trial-cited literature (165)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| Pharmacogenomics of the Etonogestrel Contraceptive Implant: A Genome-Wide Association Study of Steady-State Etonogestrel Concentrations. | O&G open | 2025 | 0 |
| Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). | Leukemia | 2024 | 35 |
| Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. | Leukemia research | 2024 | 8 |
| Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. | Future oncology (London, England) | 2024 | 1 |
Showing 5 of 165 papers.
Protein variant mentions (57)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A757T | 5 | 2013 to 2017 | PMID 29296819, PMID 27069254, PMID 25741868 |
| p.C401F | 1 | 2015 | PMID 25741868 |
| p.C401R | 1 | 2015 | PMID 25741868 |
| p.C404R | 1 | 2018 | PMID 29528181 |
| p.C840W | 1 | 2015 | PMID 25741868 |
Showing 5 of 57 variants.
Literature-extracted relations (18)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. | 2024 |
| Myelodysplastic Syndromes | Disease | associate |
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. | 2024 |
| Primary Immunodeficiency Diseases | Disease | associate |
Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. | 2019 |
| Myelodysplastic Syndromes | Disease | associate |
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. | 2018 |
| Myelodysplastic Syndromes | Disease | associate |
Myelodysplastic syndromes: Contemporary review and how we treat. | 2016 |
Showing 5 of 18 relation assertions.
Organizations publishing (262)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 14 | 2009 to 2024 |
| Memorial Sloan Kettering Cancer Center | Hospital | 9 | 2012 to 2021 |
| The University of Texas System | Academic | 7 | 2013 to 2026 |
| University of California System | Academic | 7 | 2013 to 2024 |
| University of Florence | Academic | 7 | 2013 to 2026 |
Showing 5 of 262 organizations.
Where CBL appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
541 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.